500 related articles for article (PubMed ID: 36135056)
21. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
22. Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non-small-cell lung cancer: a case report.
Liu Y; Gao Z; Zhang C; Liu X; Liu Z; Lin X; Qian B; Jin F; Shao G; Yang Z
Anticancer Drugs; 2022 Jan; 33(1):e784-e788. PubMed ID: 34419961
[TBL] [Abstract][Full Text] [Related]
23. Major pathological remissions in a patient with stage IIIA nonsmall cell lung cancer after neoadjuvant tislelizumab combined with chemotherapy: a case report and literature review.
Li LZ; Lin SH; Wu LX; Chen T; Zhuang JN; Lai HQ; Liang ZP; Zhu WS; Li WX; Tang L; Zhang HT; Fang CT
Anticancer Drugs; 2023 Sep; 34(8):962-966. PubMed ID: 36602434
[TBL] [Abstract][Full Text] [Related]
24. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report.
Yang J; Xia H; Sun F; Zhang P; Jiang G
Ann Transl Med; 2021 Apr; 9(8):724. PubMed ID: 33987422
[TBL] [Abstract][Full Text] [Related]
26. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
[TBL] [Abstract][Full Text] [Related]
29. Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC.
Du C; Chen Y; Zhou Y; Zheng D; Zhao J; Tang J; Wu Y; Tu Z
BMC Cancer; 2023 Dec; 23(1):1260. PubMed ID: 38129808
[TBL] [Abstract][Full Text] [Related]
30. Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
Xu Y; Ma D; Qin Y; Li S; Li J; Jiang Y; Wang M; Xu Y; Zhao J; Chen M; Cheng W; Hu K; Liu H
Thorac Cancer; 2023 Jun; 14(17):1635-1639. PubMed ID: 37094918
[TBL] [Abstract][Full Text] [Related]
31. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
32. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer.
Grossi F; Pennucci MC; Serrano J; Frola C; Mereu C; Scolaro T; Ratto GB; Tixi L; Ardizzoni A
Anticancer Res; 2002; 22(6B):3519-24. PubMed ID: 12552949
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer.
Watanabe SI; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Saji H; Yoshioka H; Zenke Y; Aoki T; Tsutani Y; Okada M;
Jpn J Clin Oncol; 2017 Dec; 47(12):1112-1118. PubMed ID: 29136212
[TBL] [Abstract][Full Text] [Related]
35. An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis.
Gu L; Wang X; Sun Y; Xu Y; Niu X; Zhao R; Yao Y; Jian H; Han Y; Wei J; Chen Z; Lu S
Front Immunol; 2022; 13():938269. PubMed ID: 36059450
[TBL] [Abstract][Full Text] [Related]
36. Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer.
Tong BC; Gu L; Wang X; Wigle DA; Phillips JD; Harpole DH; Klapper JA; Sporn T; Ready NE; D'Amico TA
J Thorac Cardiovasc Surg; 2022 Feb; 163(2):427-436. PubMed ID: 33985811
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer.
Zhao ZR; Yang CP; Chen S; Yu H; Lin YB; Lin YB; Qi H; Jin JT; Lian SS; Wang YZ; You JQ; Zhai WY; Long H
Oncoimmunology; 2021; 10(1):1996000. PubMed ID: 34712513
[TBL] [Abstract][Full Text] [Related]
38. Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review.
Cui G; Qu D; Bai Y; Sun X; Li Y; Yang Y
Oncol Lett; 2023 Sep; 26(3):388. PubMed ID: 37559583
[TBL] [Abstract][Full Text] [Related]
39. Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report.
Li W; Zhai C; Che J; Wang W; Liu B
J Cardiothorac Surg; 2022 Jan; 17(1):10. PubMed ID: 35034650
[TBL] [Abstract][Full Text] [Related]
40. Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network.
Pilon Y; Rokah M; Seitlinger J; Sepesi B; Rayes RF; Cools-Lartigue J; Najmeh S; Sirois C; Mulder D; Ferri L; Abdulkarim B; Ezer N; Fraser R; Camilleri-Broët S; Fiset PO; Wong A; Sud S; Langleben A; Agulnik J; Pepe C; Shieh B; Hirsh V; Ofiara L; Owen S; Spicer JD
Clin Lung Cancer; 2024 May; 25(3):e133-e144.e4. PubMed ID: 38378398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
